COMPANY PROFILE
Pulike Biological Engineering, Inc is a state-level high-tech enterprise mainly engaged in the R&D, production and marketing of veterinary biological products and drugs, and its innovative ability and comprehensive strength rank among the top in the industry.
Pulike has 6 wholly-owned subsidiaries: Luoyang Huizhong Biological Technology Co., Ltd., Luoyang Huizhong Animal Medicine Co., Ltd., Henan XinZhengHao Bioengineering Co., Ltd., Luoyang Sino-Science Technology Park Co., Ltd. and Pulike (NJ) Biological Technology Co., Ltd.,Luoyang Huiizon Animal Health Co., Ltd..
Pulike is a listed company on the Shanghai Stock Exchange (stock code: 603566),
a vice-chairman unit of China Animal Husbandry and Veterinary Medicine Association, a vice-chairman unit of China Veterinary Medicine Association, and a national technological innovation demonstration enterprise.
And we are the vice-chairman unit of the National Veterinary Drug Industry Technology Innovation Alliance, the National Pig Industry Technology Innovation Alliance, and the National Animal Health Management and Food Safety Innovation Alliance.
Pulike Biological Engineering, Inc is a state-level high-tech enterprise mainly engaged in the R&D, production and marketing of veterinary biological products and drugs, and its innovative ability and comprehensive strength rank among the top in the industry.
Pulike has five wholly-owned subsidiaries: Luoyang Huizhong Biological Technology Co., Ltd., Luoyang Huizhong Animal Medicine Co., Ltd., Henan XinZhengHao Bioengineering Co., Ltd., Luoyang Sino-Science Technology Park Co., Ltd. and Pulike (NJ) Biological Technology Co., Ltd..
Pulike is a listed company on the Shanghai Stock Exchange (stock code: 603566),
a vice-chairman unit of China Animal Husbandry and Veterinary Medicine Association, a vice-chairman unit of China Veterinary Medicine Association, and a national technological innovation demonstration enterprise.
And we are the vice-chairman unit of the National Veterinary Drug Industry Technology Innovation Alliance, the National Pig Industry Technology Innovation Alliance, and the National Animal Health Management and Food Safety Innovation Alliance.

Enterprise purpose: Golden quality, benefit mankind
Development concept: Innovation creates future
Management Strategy: Decent and prudent operation
Talent concept:Professional and career sync
BRAND DISPLAY
DEVELOPMENT HISTORY
-
2020
2020, the GMP production line for pet drugs has been added to Pulike’s subsidiary Huizhong Animal Medicine Co., Ltd.!
-
2019
2019, Pulike acquired Merial Nanjing and changed its name to "Pulike (NJ) Biological Technology Co., Ltd.", obtained the production qualification of highly pathogenic avian influenza (H5+H7).
-
2018
2018, Capul Biological Pharmaceutical Co., Ltd. was jointly established with China Animal Husbandry Industry, and obtained the production qualification of foot-and-mouth disease vaccine.
-
2015
2015, Pulike successfully listed on the Shanghai Stock Exchange. Stock abbreviation: Pulike, stock code: 603566
-
2013
2013, the main production base of Luoyang Huizhong Biological Technology Co., Ltd. was completed.
-
2012
2012, the company's R&D center was jointly rated as a national enterprise technology center by the National Development and Reform Commission and other five ministries and commissions.
-
2009
2009, the National Research Center for Veterinary Medicine settled in the company.
-
2005
2005, Henan XinZhengHao Bioengineering Co., Ltd. was established, which is a strategic alliance enterprise with Huizhong, taking the lead in the research of compound disinfectants in China.
-
2002
2002, Pulike Biological engineering Co., Ltd. was registered and completed the domestic first-class GMP production base of inactivated veterinary vaccine and GMP lyophilized powder workshop.
-
1995
1995, Huizhong was established, the first launching of Traditional Chinese Veterinary Medicine extraction products “Chicken disease clear” and “Gankang” oral solution.
Contact Us

E-mail:global@pulike.com.cn
Headquarter Address: No.15 Zhenghe Road,
Luolong District, Luoyang City, Henan Province, China

Pulike
Bioengineering

Pulike Swine

Pulike Poultry
◎2011-2014 PULIKE BIOTECH ALL RIGHTS RESERVED.


Pulike Bioengineering
Pulike Biological Engineering, Inc is a state-level high-tech enterprise mainly engaged in the R&D, production and marketing of veterinary biological products and drugs, and its innovative ability and comprehensive strength rank among the top in the industry.
Pulike has 6 wholly-owned subsidiaries: Luoyang Huizhong Biological Technology Co., Ltd., Luoyang Huizhong Animal Medicine Co., Ltd., Henan XinZhengHao Bioengineering Co., Ltd., Luoyang Sino-Science Technology Park Co., Ltd. and Pulike (NJ) Biological Technology Co., Ltd.,Luoyang Huiizon Animal Health Co., Ltd..
Pulike is a listed company on the Shanghai Stock Exchange (stock code: 603566), a vice-chairman unit of China Animal Husbandry and Veterinary Medicine Association, a vice-chairman unit of China Veterinary Medicine Association, and a national technological innovation demonstration enterprise.
And we are the vice-chairman unit of the National Veterinary Drug Industry Technology Innovation Alliance, the National Pig Industry Technology Innovation Alliance, and the National Animal Health Management and Food Safety Innovation Alliance.
Pulike Biological Engineering, Inc is a state-level high-tech enterprise mainly engaged in the R&D, production and marketing of veterinary biological products and drugs, and its innovative ability and comprehensive strength rank among the top in the industry.
Pulike has five wholly-owned subsidiaries: Luoyang Huizhong Biological Technology Co., Ltd., Luoyang Huizhong Animal Medicine Co., Ltd., Henan XinZhengHao Bioengineering Co., Ltd., Luoyang Sino-Science Technology Park Co., Ltd. and Pulike (NJ) Biological Technology Co., Ltd..
Pulike is a listed company on the Shanghai Stock Exchange (stock code: 603566), a vice-chairman unit of China Animal Husbandry and Veterinary Medicine Association, a vice-chairman unit of China Veterinary Medicine Association, and a national technological innovation demonstration enterprise.
And we are the vice-chairman unit of the National Veterinary Drug Industry Technology Innovation Alliance, the National Pig Industry Technology Innovation Alliance, and the National Animal Health Management and Food Safety Innovation Alliance.
Pulike Company has always taken innovation as the source power of enterprise development, Pulike has a National Research Center for Veterinary Medicine approved by the Ministry of Science and Technology, a national enterprise technology center jointly approved by the National Development and Reform Commission and the Ministry of Science and Technology and other five ministries and commissions, and a national and local joint engineering laboratory for the development of diagnostic reagents and vaccines for animal infectious diseases approved by the National Development and Reform Commission. The research and development center covers an area of nearly 20,000 square meters, with more than 270 technical research and development staff with doctoral and master's degree as the mainstay; It has successively established extensive industry-university-research cooperation with Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Lanzhou Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Institute of Microbiology of the Chinese Academy of Sciences, Military Veterinary Research Institute of Chinese Academy of Medical Sciences, China Agricultural University, Nanjing Agricultural University and other institutions.
Pulike has always maintained high-intensity investment on R&D, in recent years, the proportion of R&D expenses in operating income has always remained above 10%.
Based on the company's strong innovation ability and relying on the R&D platform with high standards and high starting point, Pulike has undertaken nearly 40 major national, provincial and municipal science and technology projects such as the 863 Program of the Ministry of Science and Technology, the National Science and Technology Support Program, the National Development and Reform Commission's high-tech industrialization project, the major science and technology project of Henan Province, and the major science and technology project of Luoyang City. As of June 2020, 55 new veterinary drug certificates have been obtained, has applied for 500 invention patents and obtained 233 invention patents, including 24 international invention patents and more than 10 national, provincial and municipal scientific and technological achievements awards, and has become a leading enterprise in scientific and technological innovation in the domestic animal medicine industry.
In recent years, the company has made great breakthroughs in the industrialization technologies such as reverse genetic technology, bacterial artificial chromosome, prokaryotic and eukaryotic expression technology, high-density cell suspension culture technology, high-density fermentation and antigen extraction, concentration and purification technology, etc., and is at the leading level in product structure innovation such as genetic engineering vaccine and macrolide animal-specific antibiotics.
Among them, the genetic engineering triple inactivated vaccine (ND+IB+AI)(Re-9 strain) led Chinese H9 subtype avian influenza vaccine into the era of genetic engineering vaccine; The genetic engineering subunit vaccine of pure virus-like granular porcine circovirus type 2 and the combined vaccine of mycoplasma and circovirus with aqueous adjuvant for swine, which have been successfully developed undergoing 7 years, have been launched on the market, leading the iterative upgrade of porcine circovirus vaccine in the industry.
In 2019, the inactivated vaccine PuWeiJing against porcine pseudorabies with variant (HN1201-ΔgE strain) was successfully launched on the market, which will make a positive contribution to the prevention, control and purification of porcine pseudorabies in China.
Pulike adheres to the purpose of “Golden quality, benefit mankind”, follows the development concept of “Innovation creates future”, abides by the development strategy of “Decent and prudent operation”, carry forward the enterprise spirit of “Integrity and pragmatism, first class orientation”. Pursuing research, production and promotion of new veterinary vaccines and drugs, with high starting point and high standard, committed to building a world brand in Chinese animal health product industry.